Revenue
$265.5m
+7.4% ↑ vs $247.2m
EBITDA rose just 3.2% on 7.4% revenue growth, while a -10.9% effective tax rate drove NPAT up 104.5% and development capex was paused.
Revenue context before the current result.
EBITDA margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Key metrics
FY24 vs FY23
Revenue
$265.5m
+7.4% ↑ vs $247.2m
EBITDA
$82.6m
+3.2% ↑ vs $80m
Net profit after tax
$31.5m
+104.5% ↑ vs $15.4m
Net cash inflow from operating activities
$85.4m
+21.6% ↑ vs $70.2m
Declared dividend per share
—
— vs 1.3c
Total assets
$2.8b
+9.3% ↑ vs $2.5b
What changed
Profit before tax of $28.4m sits below NPAT, which means the cleaner operating read is materially weaker than the headline. Revenue grew 7.4% to $265.5m and EBITDA grew only 3.2% to $82.6m.
The more economically significant move sits below the P&L. Capex was cut from $164.0m to $52.0m (-68.3%), capex intensity dropped from 66.3% to 19.6% of revenue, and gross borrowings ended at $640.5m with net debt of $633.0m — leverage of 7.7x EBITDA. Operating cash flow rose 21.6% to $85.4m and FCF pre-lease turned positive at $33.4m (versus -$93.8m).
What matters
A $112m cut in capex in a single year, for a retirement-village operator whose Village Operations segment depends on new units to generate development margin and DMF, is a strategic shift rather than a timing effect. The pullback funded the positive FCF, not earnings growth.
Headline earnings growth is not repeatable. Stripping the tax benefit, PBT of $28.4m sits below NPAT of $31.5m and EBITDA grew only 3.2%. Investors should anchor on PBT and EBITDA trends, not the 104.5% NPAT figure, when judging operating momentum. Care Operations (77.8% of revenue) earned a derived segment margin of just 5.8%, so the group result still leans on Village Operations economics.
Leverage of 7.7x EBITDA constrains flexibility. With net debt at $633.0m, $7.5m of cash, and ROE of just 3.1%, the company has limited capacity to simultaneously fund development, service debt, and pay dividends at prior levels. The FY24 dividend declared in this release is not disclosed in the extraction, against 1.3 cps in the comparable, which itself signals a tightening capital posture.
Expectations
HY24 generated revenue of $131.6m (49.6% of the full year) and EBITDA of $37.6m (45.6%), so revenue was roughly balanced first-half/second-half while EBITDA was second-half weighted. HY24 NPAT of $35.2m exceeded the full-year $31.5m, implying a second-half NPAT loss of roughly $3.7m once tax benefits and revaluation effects unwound — confirming that the doubling in reported NPAT is concentrated in the first half and partly reverses in the second.
This release does not support a clean read on a return to a normalised development cadence, on dividend resumption, or on the leverage trajectory. Those remain open.
Quality of result
However, FCF turned positive primarily because capex was cut by $112m, not because earnings rose. That means the cash improvement is not a durability signal — it is a deliberate slowdown in growth investment, which lowers future development margin and resale capacity.
The NPAT line itself is heavily timing-driven: a -10.9% effective tax rate (tax benefit) added several million dollars that will not recur on the same scale, and the disclosed gains include $67.9m of capital gains within the result. Underlying EBITDA growth of 3.2% on 7.4% revenue growth implies a margin contraction, consistent with cost pressure outpacing pricing. Trade debtors at $124.9m represent 171.7 receivable days, which is high in absolute terms but typical of retirement-village receivables tied to resident loan and resale settlement timing rather than ordinary trade debt.
Unresolved
This briefing cannot assess Oceania's underlying property revaluation movements, ORA and resident-loan flows, or unit sales pricing dynamics, because those line items are not provided in the supplied extraction.
Chat
Ask follow-up questions about Oceania Healthcare's FY24 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
Annual Report
FY24 / financial reportMedia Release
FY23 / financial reportResults Announcement
FY23 / results announcementInterim Report
HY24 / financial reportInvestor Presentation
HY24 / results presentationMedia Release
HY24 / media releaseResults Announcement
HY24 / results announcementInvestor Presentation
FY24 / commentaryCEO Address
HY24 / commentaryChair Address
HY24 / commentaryPresentation
HY24 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Leverage and balance-sheet risk
Net debt / EBITDA is 7.70x for this result.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 0.0pp, with a distortion flag in the result.
Cash conversion quality
This result converted 103.4% of EBITDA to operating cash flow, +15.7pp versus the prior comparable period.
Working-capital pressure
Debtor days were 172 days for this result.
Get the next Oceania Healthcare briefing and related NZX reporting-season updates by email.